Aventis Submits US and EU Regulatory Applications for the Use of Taxotere(R) in Patients with Early-Stage Breast Cancer New indication would expand the role of Taxotere(R) in the treatment of breast cancer BRIDGEWATER, N.J., March 25 /PRNewswire-FirstCall/ -- Aventis announced today that it has submitted registrational applications for the use of Taxotere(R) (docetaxel) Injection Concentrate in treating women with early-stage operable breast cancer with involved axillary lymph nodes in the United States and the European Union. The applications are based on data from a large Phase III study that found the combination of Taxotere(R), doxorubicin and cyclophosphamide (TAC) to significantly improve overall survival in women with early-stage breast cancer and reduce their risk of a relapse compared with the standard regimen of 5-fluorouracil, doxorubicin and cyclophosphamide (FAC). These data, from the Breast Cancer International Research Group (BCIRG) 001/ TAX 316 study, were presented at the San Antonio Breast Cancer Symposium on December 5, 2003 and demonstrated that women with node-positive, early-stage breast cancer who received a Taxotere(R)-based chemotherapy regimen after surgery experienced a 30 percent reduction in the risk of death at a 55-month follow-up and a 28 percent reduction in the chance of their cancer returning as compared to women treated with a commonly used, standard (post-surgery) adjuvant regimen. A similar benefit for TAC over FAC was observed regardless of nodal, hormone-receptor or HER-2/neu status. "The extension of the use of Taxotere(R) in patients with early-stage breast cancer may provide an important treatment option for women throughout the world," states Dr. Susan Arbuck, Vice President and Global Head,Oncology Therapeutic Area at Aventis. "These data on which the submissions are based reflect nearly five years of follow-up that demonstrate Taxotere(R) extends the lives of women with node positive disease." Breast Cancer Breast cancer is the most common cancer among women other than skin cancer. It is the second-leading cause of cancer death in women after lung cancer -- and is the leading cause of cancer death among women ages 40 to 59. More than 1,000,000 new cases of breast cancer are reported worldwide annually and more than 300,000 women die each year from the disease. The risk of a woman developing breast cancer during her lifetime is approximately 11 percent (about one in nine of all women), with about three to four percent dying of the disease. About Taxotere(R) Taxotere(R), a drug in the taxoid class of chemotherapeutic agents, inhibits cancer cell division by essentially "freezing" the cell's internal skeleton, which is comprised of microtubules. Microtubules assemble and disassemble during a cell cycle. Taxotere(R) promotes their assembly and blocks their disassembly, thereby preventing many cancer cells from dividing and resulting in cancer cell death. Taxotere(R) is currently approved in the United States to treat patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy, and patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with cisplatin, who had not received prior chemotherapy. It also is approved for patients with unresectable locally advanced or metastatic NSCLC after failure of prior platinum-based chemotherapy. Among patients receiving Taxotere(R) the most common severe adverse events were low blood cell count, fatigue, diarrhea, and mouth and throat irritation. The most common non-severe side effects include hair loss, numbness, a tingling and/or burning sensation, rash, nail changes, nausea, vomiting, and muscle pain. Less common severe or potentially life threatening side effects include fluid retention, infections, and allergic reactions. Patients 65 years of age or older may experience some side effects more frequently. For more information about Taxotere(R), visit http://www.taxotere.com/ or see full prescribing information including boxed WARNINGS. For more information about ongoing clinical trials, please call 1-800-RxTrial or visit http://www.aventisoncology.com/. About Aventis Aventis is dedicated to treating and preventing disease by discovering and developing innovative prescription drugs and human vaccines. In 2003, Aventis generated sales of euro 16.79 billion (US $18.99), invested euro 2.86 billion (US $3.24) in research and development and employed approximately 69,000 people in its core business. Aventis corporate headquarters are in Strasbourg, France. The company's prescription drugs business is conducted in the U.S. by Aventis Pharmaceuticals Inc., which is headquartered in Bridgewater, New Jersey. For more information, please visit: http://www.aventis-us.com/. Statements in this news release containing projections or estimates of revenues, income, earnings per share, capital expenditures, capital structure, or other financial items; plans and objectives relating to future operations, products, or services; future economic performance; or assumptions underlying or relating to any such statements, are forward-looking statements subject to risks and uncertainties. Actual results could differ materially depending on factors such as the timing and effects of regulatory actions, the results of clinical trials, the company's relative success developing and gaining market acceptance for new products, the outcome of significant litigation, and the effectiveness of patent protection. Additional information regarding risks and uncertainties is set forth in the current Annual Report on Form 20-F of Aventis on file with the Securities and Exchange Commission and in the current Annual Report -"Document de Reference"- on file with the "Autorite des marches financiers" in France. Pursuant to Article 7 of the COB Regulation no. 2002-04, this press release was transmitted to the Autorite des marches financiers before its release. DATASOURCE: Aventis Pharmaceuticals CONTACT: Corinne Hoff of Aventis Global Media Relations, +33-3-88-9919-16, ; or Lisa Kennedy of Aventis U.S. Product Communications, +1-908-243-6361, ; or Marisol Peron of Aventis U.S. Communications, +1-908-243-7592, Web site: http://www.aventisoncology.com/ http://www.aventis-us.com/ http://www.taxotere.com/

Copyright